In the Present Study, lornoxicam and curcumin entrapped ethosomal gel for transdermal drug delivery was prepared by using various concentrations of phospholipids and ethanol. Novel ethosome gel was developed and evaluated for its anti-inflammatory activity. Therefore, drug of herbal origin will also be formulated separately and compared with that of the formulations developed with the synthetic drug. The vesicle size and entrapment efficiency of lornoxicam ethosomes dispersions was found to be in the range of 356.45±0.14to 436.65±0.23 And 58.98±0.32 To 71.56±0.45% and the vesicle size and entrapment efficiency of curcumin ethosomes dispersions was found to be in the range of 498.56±0.23 to 312.25±0.58and 60.25±0.21 to 73.23±0.14%. In formulation lef1-lef6 (for lornoxicam) and cef1- cef6 (for curcumin) amount of ethanol and phospholipid were optimized, it was found that lef4 having higher ethanol shows good entrapment efficiency and smaller vesicle size compared to other formulation. optimized batch of ethosomes formulation (LEF4 And CEF4) was incorporated into gel base concentration 0.5, 1 and 1.5% w/w. Prepared Gel was evaluated for physical characteristic, ph, washability, spreadability, viscosity and in vitro drug release study.The regression coefficient values of were compared, it was observed that ‘R’ Values Of Formulation Was Maximum In First Order I.E 0.994 And 0.983 For LG2 And CG3 respectively. Release data of both the formulation indicate that the lornoxicam loaded ethosome gel showed maximum release 78.98% after 8 hrs while curcumin loaded ethosomes gel showed only 71.56% drug release after 8 hrs.
Cite this article:
Swati Sejwani, Vinod Dhote, Priyanka Chaturvedi. Development of novel formulations from natural and synthetic origin drugs for effective management of inflammation. Research J. Topical and Cosmetic Sci. 2020; 11(2):70-76. doi: 10.5958/2321-5844.2020.00013.8
Swati Sejwani, Vinod Dhote, Priyanka Chaturvedi. Development of novel formulations from natural and synthetic origin drugs for effective management of inflammation. Research J. Topical and Cosmetic Sci. 2020; 11(2):70-76. doi: 10.5958/2321-5844.2020.00013.8 Available on: https://rjtcsonline.com/AbstractView.aspx?PID=2020-11-2-5
1. Pradhan, M.; Singh, D.; Singh, M. R., Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. J Control Release 2013, 170 (3), 380-95.
2. Katare, O. P.; Raza, K.; Singh, B.; Dogra, S., Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian journal of dermatology, venereology and leprology 2010, 76 (6), 612-21.
3. Nimisha; Rizvi, D. A.; Fatima, Z.; Neema; Kaur, C. D., Antipsoriatic and Anti-inflammatory Studies of Berberis aristata Extract Loaded Nanovesicular Gels. Pharmacognosy magazine 2017, 13 (Suppl 3), S587-s594.
4. Wollina, U.; Tirant, M.; Vojvodic, A.; Lotti, T., Treatment of Psoriasis: Novel Approaches to Topical Delivery. Open access Macedonian journal of medical sciences 2019, 7 (18), 3018-3025.
5. Hallan, S. S.; Sguizzato, M., Design and Characterization of Ethosomes for Transdermal Delivery of Caffeic Acid. 2020, 12 (8).
6. Fu, X.; Shi, Y., Ethosomal Gel for Improving Transdermal Delivery of Thymosin β-4. 2019, 14, 9275-9284.
7. Agrawal, Y. O.; Mahajan, U. B., Methotrexate-Loaded Nanostructured Lipid Carrier Gel Alleviates Imiquimod-Induced Psoriasis by Moderating Inflammation: Formulation, Optimization, Characterization, In-Vitro and In-Vivo Studies. 2020, 15, 4763-4778.
8. Shen, L. N.; Zhang, Y. T.; Wang, Q.; Xu, L.; Feng, N. P., Enhanced in vitro and in vivo skin deposition of apigenin delivered using ethosomes. Int J Pharm 2014, 460 (1-2), 280-8.
9. Paolino, D.; Lucania, G.; Mardente, D.; Alhaique, F.; Fresta, M., Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release 2005, 106 (1-2), 99-110.
10. Jain, S.; Patel, N.; Madan, P.; Lin, S., Formulation and rheological evaluation of ethosome-loaded carbopol hydrogel for transdermal application. Drug Dev Ind Pharm 2016, 42 (8), 1315-24.
11. An, K.; Sun, Y.; Wu, Y.; Yuan, H.; Cui, Z.; Xu, L., Preparation and in vitro percutaneous penetration of simvastatin ethosome gel. Artificial cells, nanomedicine, and biotechnology 2013, 41 (5), 315-8.
12. Zhu, X.; Li, F.; Peng, X.; Zeng, K., Formulation and evaluation of lidocaine base ethosomes for transdermal delivery. Anesthesia and analgesia 2013, 117 (2), 352-7.
13. Apriani, E. F.; Rosana, Y.; Iskandarsyah, I., Formulation, characterization, and in vitro testing of azelaic acid ethosome-based cream against Propionibacterium acnes for the treatment of acne. Journal of advanced pharmaceutical technology and research 2019, 10 (2), 75-80.
14. Liu, X.; Liu, H.; Liu, J.; He, Z.; Ding, C.; Huang, G.; Zhou, W.; Zhou, L., Preparation of a ligustrazine ethosome patch and its evaluation in vitro and in vivo. Int J Nanomedicine 2011, 6, 241-7.
15. Mao, Y. T.; Hua, H. Y.; Zhang, X. G.; Zhu, D. X.; Li, F.; Gui, Z. H.; Zhao, Y. X., Ethosomes as delivery system for transdermal administration of vinpocetine. Die Pharmazie 2013, 68 (5), 381-2.